Huaren Pharmaceutical Co Ltd operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Huaren Pharmaceutical Co Ltd with three other
companies in this sector in China:
Porton Pharma Solutions Ltd
sales of 1.18 billion Chinese Renmimbi [US$170.75 million]
of which 83%
was Pharmaceutical R&D Production),
Hebei Changshan Biochemical Pharmaceutical Co Ltd
(1.42 billion Chinese Renmimbi [US$204.79 million]
of which 100%
was Biomedicine), and
Asymchem Laboratories Tian Jin Co Ltd
(1.42 billion Chinese Renmimbi [US$205.20 million]
of which 100%
was Pharmaceutical industry).
During the year ended December of 2017, sales at
Huaren Pharmaceutical Co Ltd were 1.31 billion Chinese Renmimbi (US$189.17 million).
increase of 5.0%
versus 2016, when the company's sales were 1.25 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Huaren Pharmaceutical Co Ltd
(and since 2012, sales have increased a total of 133%).
Sales of Medicine Industry saw an increase
that was more than double the company's growth rate: sales were up
16.8% in 2017, from
1.00 billion Chinese Renmimbi to 1.17 billion Chinese Renmimbi.
Not all segments of Huaren Pharmaceutical Co Ltd experienced an increase in sales in 2017:
sales of Medicine Commerce fell 42.3% to 143.54 million Chinese Renmimbi.